Edge Therapeutics racks up about $72.5 mln
Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics' board of directors.
